Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carrier-platin
- Development stage
- Preclinical
- Lead developer
- Methodist Hospital Research Institute
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Carrier-platin is a novel macromolecular platinum-based chemotherapeutic agent developed to overcome the limitations of small-molecule platinum drugs like cisplatin and oxaliplatin. It consists of L-aspartic acid-chelated platinum moieties (Asp-Pt) conjugated to a poly(L-glutamic acid/L-aspartic acid) backbone. This poly(amino acid) conjugation strategy is designed to improve pharmacokinetics, increase tumor accumulation through the enhanced permeability and retention (EPR) effect, and bypass multi-drug resistance (MDR) proteins that often lead to treatment failure. In preclinical studies, carrier-platin demonstrated potent anti-tumor efficacy in colorectal and ovarian cancer models, including those resistant to cisplatin and oxaliplatin, while maintaining a superior safety profile with reduced hematotoxicity and weight loss compared to standard platinum therapies.
- Other names
- polymeric-Pt macromolecule
02
Targets
DNA
Beyond the preview
Go deeper on carrier-platin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carrier-platin.